Search Results

Press Releases

Bitterroot Bio to Present Anti-CD47 Research at American Heart Association Annual Scientific Session 2025

November 3, 2025

·

1 min read

Press Releases

Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

June 2, 2025

·

3 min read

Drug Development

Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers

Bitterroot Bio today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers.

April 29, 2024

·

2 min read

Business

Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary

Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of cardio-immunology, announced the appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary.

June 4, 2024

·

3 min read

Business

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology

Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, announced a multi-year research collaboration agreement.

February 26, 2024

·

2 min read

Press Releases

Bitterroot Bio to Present Detailed Results from Phase 1 Study of BRB-002 at American College of Cardiology Annual Scientific Session 2025

March 17, 2025

·

1 min read

Drug Development

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference

Bitterroot Bio has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA.

October 30, 2023

·

1 min read

Press Releases

Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

January 9, 2025

·

3 min read

Press Releases

Bitterroot Bio Completes Enrollment in Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

October 29, 2024

·

1 min read

Biotech Bay

Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology

Bitterroot Bio announced a $145 million Series A financing round co-led by ARCH Venture Partners and Deerfield Management with participation from GV, Koch Disruptive Technologies, Alexandria Venture Investments, and others.

June 7, 2023

·

7 min read